QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VI Duplicate Management of Suspected Adverse Reaction Reports

Test your understanding of the concepts covered by GVP Module VI: Duplicate Management of Suspected Adverse Reaction Reports.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A database algorithm identifies two candidate reports with the same product, country, age, unusual laboratory finding, and reporter. What should happen next?

The system should automatically delete one report The reports should be treated as confirmed duplicates without review A trained reviewer should assess the combined evidence, including the clinical narrative and timeline The reports should automatically be retained as separate because no single field proves duplication

Question 2 of 10 Which principle best defines an ICSR duplicate?

Two reports containing the same adverse reaction term Two reports concerning the same underlying individual case Two reports received through different reporting channels Two reports involving the same medicinal product

Question 3 of 10 Which approach provides the strongest basis for duplicate assessment?

Use one highly specific field as a definitive identifier Compare multiple patient, product, event, temporal, reporter, and narrative elements Compare only the coded adverse reaction terms Compare only the case creation dates

Question 4 of 10 How should reporter identity generally be used in duplicate assessment?

A shared reporter proves that two reports concern the same patient Different reporters prove that the reports concern different patients Reporter identity is supporting evidence that must be interpreted with other case information Reporter identity should never be considered because it is not clinical information

Question 5 of 10 Which factor may legitimately influence selection of a master or primary case?

The record with the most attractive case identifier Completeness, earliest valid receipt, source quality, regulatory status, and system architecture The record received from the channel with the shortest name The record with the fewest adverse reactions

Question 6 of 10 Why can incorrect duplicate management materially affect pharmacovigilance activities?

It changes only the appearance of the safety database and has no analytical effect It can cause double counting or loss of cases, affecting signals, frequencies, aggregate reports, and risk assessments It affects only the ability to identify the original reporter It primarily delays product registration rather than affecting safety conclusions

Question 7 of 10 What is the principal risk of a false-positive duplicate decision?

Double counting the same patient Loss or distortion of information from genuinely different cases Failure to identify a common product synonym Automatic escalation of every case to signal detection

Question 8 of 10 Two unrelated patients receive the same product and develop the same common adverse reaction. What is the most appropriate conclusion?

The reports are duplicates because the product and reaction are identical The reports should be merged unless their case identifiers differ The reports should remain separate unless broader evidence supports that they describe the same patient The reports should be excluded from signal detection

Question 9 of 10 A branded product appears in one report and only the active substance appears in another. What is the appropriate duplicate-management response?

Treat them as unrelated because the product names are not identical Assess whether the brand and active substance represent the same exposure, together with other matching evidence Merge them automatically because all products with the same active substance are always duplicates Exclude the active-substance report from the safety database

Question 10 of 10 Why should clinical narratives be reviewed in difficult duplicate assessments?

Narratives replace the need to compare patient identifiers Narratives may reveal shared admissions, investigations, treatment sequences, or distinctive events not captured in coded fields Narratives are legally more authoritative than all structured data Narratives are used only to determine reporter qualification

QPPV.com

Knowledge Assessment: GVP Module VI Duplicate Management of Suspected Adverse Reaction Reports

Cookie Settings